2024-09-30 - Analysis Report
## Vertex Pharmaceuticals Inc. (VRTX) Stock Analysis

**1. Performance Comparison:**

Vertex Pharmaceuticals Inc. (VRTX) has outperformed the S&P 500 (VOO) with a cumulative return of 169.77% compared to VOO's 133.28%. This represents a difference of 36.49%. This outperformance places VRTX in the 72.16th percentile of its historical performance range against the S&P 500.

**2. Recent Price Action:**

* Closing Price: $462.85
* 5-Day Moving Average: $462.69
* 20-Day Moving Average: $473.52
* 60-Day Moving Average: $481.13

The current price is below all three moving averages, indicating potential downward pressure in the short term.

**3. Technical Indicators:**

* RSI: 44.07
* PPO: -0.34
* Delta_Previous_Relative_Divergence: -14.25
* Expected Return: 4.48%

The RSI suggests the stock is currently in neutral territory. The PPO is negative, implying a downtrend. The negative Delta_Previous_Relative_Divergence indicates a recent short-term decline. The Expected Return represents a potential 5-year maximum return on investment. 

**4. Recent Earnings & Outlook:**

| Date       | EPS    | Revenue |
|------------|--------|---------|
| 2024-08-02 | -13.92 | 2.65 B$ |
| 2024-05-07 | 4.26   | 2.69 B$ |
| 2023-11-07 | 4.01   | 2.48 B$ |
| 2023-08-02 | 3.55   | 2.49 B$ |
| 2023-08-02 | 3.55   | 2.49 B$ |

The most recent earnings report (2024-08-02) showed a significant EPS miss compared to analyst expectations. This has likely contributed to the recent downward pressure on the stock price.

**5. News & Recent Issues:**

* **Recent Market Outlook:** While VRTX is a leading player in the cystic fibrosis market, the recent earnings miss and concerns about competition have led to a decline in stock price.
* **Analyst Opinions:** While some analysts remain bullish on VRTX's long-term prospects due to its strong pipeline and market share, the recent earnings miss has caused some analysts to revise their targets downwards.
* **Performance Highlights:** VRTX's focus on developing gene-editing therapies for rare diseases remains promising. However, the company's reliance on a single product line (CFTR modulators) makes it vulnerable to competition.

**6. Overall Analysis:**

Vertex Pharmaceuticals Inc. (VRTX) has a strong track record of outperforming the market. However, the recent earnings miss and concerns about competition have created some uncertainty. While the company's long-term prospects remain promising, the stock's short-term outlook appears to be under pressure. 

**7. Conclusion:**

VRTX remains a potentially attractive investment for long-term investors seeking exposure to the gene-editing therapy market. However, the recent earnings miss and concerns about competition should be closely monitored. Investors should consider their risk tolerance and investment horizon before making any investment decisions.